Vertex Pharmaceuticals Incorporated engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene. It is also developing VX-659 and VX-445 that are Phase III clinical trials; VX-121, a cystic fibrosis transmembrane conductance regulator corrector that is in Phase I/II clinical trial; VX-150, an inhibitor that is in Phase IIb clinical trial for acute pain; CTX001 that is in Phase I/II clinical trial for the treatment of beta-thalassemia and sickle cell diseases; and a novel drug candidate, which is in Phase I clinical trial for the treatment for alpha-1 antitrypsin deficiency. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. Vertex Pharmaceuticals Incorporated has collaborations with CRISPR Therapeutics AG, Arbor Biotechnologies, Inc., Moderna Therapeutics, Inc., Genomics plc, Merck KGaA, Darmstadt, Germany, and X-Chem, Inc., as well as Janssen Pharmaceuticals, Inc. and Merck KGaA. The company was founded in 1989 and is headquartered in Boston, Massachusetts.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
Phone617-341-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.05 billion
Profitability
Miscellaneous
Employees2,500
Next Earnings Date4/30/2019 (Confirmed)
OptionableOptionable
Vertex Pharmaceuticals (NASDAQ:VRTX) Frequently Asked Questions
What is Vertex Pharmaceuticals' stock symbol?
Vertex Pharmaceuticals trades on the NASDAQ under the ticker symbol "VRTX."
How will Vertex Pharmaceuticals' stock buyback program work?
Vertex Pharmaceuticals announced that its board has approved a share repurchase plan on Thursday, February 1st 2018, which permits the company to buyback $500,000,000.00 in shares, according to EventVestor. This buyback authorization permits the company to purchase shares of its stock through open market purchases. Shares buyback plans are typically a sign that the company's management believes its shares are undervalued.
How were Vertex Pharmaceuticals' earnings last quarter?
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) released its earnings results on Tuesday, February, 5th. The pharmaceutical company reported $1.30 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of $1.06 by $0.24. The pharmaceutical company had revenue of $870.11 million for the quarter, compared to analyst estimates of $818.29 million. Vertex Pharmaceuticals had a net margin of 68.81% and a return on equity of 24.15%. The company's quarterly revenue was up 33.5% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.61 EPS. View Vertex Pharmaceuticals' Earnings History.
When is Vertex Pharmaceuticals' next earnings date?
What price target have analysts set for VRTX?
21 Wall Street analysts have issued 12 month price targets for Vertex Pharmaceuticals' shares. Their forecasts range from $165.71 to $234.00. On average, they expect Vertex Pharmaceuticals' share price to reach $203.9978 in the next year. This suggests a possible upside of 21.3% from the stock's current price. View Analyst Price Targets for Vertex Pharmaceuticals.
What is the consensus analysts' recommendation for Vertex Pharmaceuticals?
21 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vertex Pharmaceuticals in the last year. There are currently 8 hold ratings and 13 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vertex Pharmaceuticals.
What are Wall Street analysts saying about Vertex Pharmaceuticals stock?
Here are some recent quotes from research analysts about Vertex Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "A significant increase in the eligible patient population for its CF drugs is driving sales growth at Vertex. Vertex’s third CF medicine, Symdeko, in a very short time, became the primary driver of growth in CF revenues in 2018. Vertex’s CF pipeline is also accelerating rapidly. However, Vertex has faced some challenges with respect to commercialization of Orkambi in ex-U.S. markets due to re-imbursement hurdles. Meanwhile, a switch in patient base to Symdeko from Orkambi is also hurting sales of the latter. Also, competitive pressure is rising in the CF market with many other companies developing triple combo CF medicines. Also, Vertex’s dependence on just the CF franchise for growth is a concern. Shares have underperformed the industry this year so far." (3/8/2019)
- 2. Maxim Group analysts commented, "Vertex announced the triple combination of VX-445, tezacaftor (tez) and ivacaftor (iva) met its primary endpoint of improvement in lung function (ppFEV1) in its dual P3 trial program which tested both F508del homozygous and F508del/min heterozygous (het/min) patients. Recall the VX-659 triple was also positive at 4 weeks (4Q18). Next up is the 24-week data (2Q19) for both triples after which Vertex will make the decision on which to file for approval in both indications." (3/6/2019)
- 3. Cantor Fitzgerald analysts commented, ". Reiterate overweight and $217 price target. This morning, Vertex announced that CFO Tom Graney has resigned effective immediately. He joined 2017, so his tenure was relatively short." (12/17/2018)
Has Vertex Pharmaceuticals been receiving favorable news coverage?
Media stories about VRTX stock have been trending somewhat positive recently, InfoTrie Sentiment reports. InfoTrie ranks the sentiment of media coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. Vertex Pharmaceuticals earned a news impact score of 1.2 on InfoTrie's scale. They also gave news coverage about the pharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the stock's share price in the next several days.
Who are some of Vertex Pharmaceuticals' key competitors?
Some companies that are related to Vertex Pharmaceuticals include Abbott Laboratories (ABT), Eli Lilly And Co (LLY), Novo Nordisk A/S (NVO), AbbVie (ABBV), Sanofi (SNY), GlaxoSmithKline (GSK), AstraZeneca (AZN), Bristol-Myers Squibb (BMY), Celgene (CELG), Bayer (BAYRY), Shire (SHPG), Zoetis (ZTS), Allergan (AGN), Regeneron Pharmaceuticals (REGN) and Takeda Pharmaceutical (TKPYY).
What other stocks do shareholders of Vertex Pharmaceuticals own?
Who are Vertex Pharmaceuticals' key executives?
Vertex Pharmaceuticals' management team includes the folowing people:
- Mr. Jeffrey Marc Leiden, Chairman, CEO & Pres (Age 63)
- Dr. David M. Altshuler, Exec. VP of Global Research & Chief Scientific Officer (Age 54)
- Mr. Michael J. Parini, Exec. VP and Chief Legal & Admin. Officer (Age 44)
- Mr. Amit K. Sachdev, Exec. VP & Chief Regulatory Officer (Age 51)
- Mr. Charles F. Wagner Jr., Exec. VP & CFO (Age 51)
Who are Vertex Pharmaceuticals' major shareholders?
Vertex Pharmaceuticals' stock is owned by a number of of retail and institutional investors. Top institutional investors include Strs Ohio (0.13%), Manning & Napier Group LLC (0.12%), Atalanta Sosnoff Capital LLC (0.09%), Retirement Systems of Alabama (0.06%), Gateway Investment Advisers LLC (0.06%) and Rhenman & Partners Asset Management AB (0.06%). Company insiders that own Vertex Pharmaceuticals stock include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey Chodakewitz, Jeffrey M Leiden, Margaret G Mcglynn, Michael Parini, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Institutional Ownership Trends for Vertex Pharmaceuticals.
Which institutional investors are selling Vertex Pharmaceuticals stock?
VRTX stock was sold by a variety of institutional investors in the last quarter, including Atalanta Sosnoff Capital LLC, Manning & Napier Group LLC, Bank of The West, Chartwell Investment Partners LLC, DNB Asset Management AS, Retirement Systems of Alabama, Lourd Capital LLC and Eqis Capital Management Inc.. Company insiders that have sold Vertex Pharmaceuticals company stock in the last year include Amit Sachdev, David Altshuler, Ian F Smith, Jeffrey M Leiden, Michael Parini, Paul M Silva, Reshma Kewalramani, Sangeeta N Bhatia, Stuart A Arbuckle and Thomas Graney. View Insider Buying and Selling for Vertex Pharmaceuticals.
Which institutional investors are buying Vertex Pharmaceuticals stock?
VRTX stock was bought by a variety of institutional investors in the last quarter, including Pennsylvania Trust Co, Pacer Advisors Inc., Calamos Advisors LLC, Dorsey Wright & Associates, Rhenman & Partners Asset Management AB, Virtu Financial LLC, Barometer Capital Management Inc. and Meeder Asset Management Inc.. View Insider Buying and Selling for Vertex Pharmaceuticals.
How do I buy shares of Vertex Pharmaceuticals?
Shares of VRTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vertex Pharmaceuticals' stock price today?
One share of VRTX stock can currently be purchased for approximately $168.16.
How big of a company is Vertex Pharmaceuticals?
Vertex Pharmaceuticals has a market capitalization of $42.99 billion and generates $3.05 billion in revenue each year. The pharmaceutical company earns $2.10 billion in net income (profit) each year or $2.83 on an earnings per share basis. Vertex Pharmaceuticals employs 2,500 workers across the globe.
What is Vertex Pharmaceuticals' official website?
How can I contact Vertex Pharmaceuticals?
Vertex Pharmaceuticals' mailing address is 50 NORTHERN AVENUE, BOSTON MA, 02210. The pharmaceutical company can be reached via phone at 617-341-6100 or via email at [email protected]
MarketBeat Community Rating for Vertex Pharmaceuticals (NASDAQ VRTX)
MarketBeat's community ratings are surveys of what our community members think about Vertex Pharmaceuticals and other stocks. Vote "Outperform" if you believe VRTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VRTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
